United States · Platforms & data · Seeking Alpha
Ideaya picks cancer drug candidate, targets human trial application in 2027

Detailed summary
Ideaya Biosciences selects IDE101, a preclinical drug candidate for cancers lacking CDKN2A, and aims to seek U.S.
Ideaya Biosciences (IDYA) on Sunday said it selected IDE101 as a drug candidate for further development to treat cancers lacking CDKN2A, a gene that normally helps prevent uncontrolled cell growth. The company aims to seek U.S. regulatory permission to begin human testing
Opening of the article, excerpted from Seeking Alpha. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (seekingalpha.com)




